Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNK01 + gemcitabine + cisplatin + cetuximab
- Development stage
- Unknown
- Lead developer
- NKGen Biotech, Inc.
- Modality
- Small Molecules, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
SNK01 is an autologous natural killer (NK) cell therapy developed by NKMax (NKGen Biotech). It consists of non-genetically modified autologous NK cells that have been expanded and activated to exhibit enhanced cytotoxicity. This specific regimen combines SNK01 with the chemotherapy agents gemcitabine and cisplatin, along with the anti-EGFR monoclonal antibody cetuximab (Erbitux). It is primarily investigated for the treatment of patients with non-small cell lung cancer (NSCLC) who have failed prior tyrosine kinase inhibitor (TKI) therapy, particularly those with EGFR mutations. The mechanism involves the direct anti-tumor activity of the NK cells, which is further augmented by cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC), alongside the cytotoxic effects of the chemotherapy doublet. Clinical data from Phase I/IIa trials (NCT04872634) demonstrated that the combination was safe and showed potential antitumor activity, with an objective response rate of 25% and a disease control rate of 100%.
- Brand names
- Erbitux
- Other names
- autologous NK cell therapy
02
Targets
DNAEGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on SNK01 + gemcitabine + cisplatin + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNK01 + gemcitabine + cisplatin + cetuximab.